Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

Phase 3

2(33.3%)

N/A

2(33.3%)

6Total

Phase 2(2)

Phase 3(2)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03503058Phase 2Completed

Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria

Role: collaborator

NCT05690841Phase 3Recruiting

FocaL Mass Drug Administration for Vivax Malaria Elimination

Role: collaborator

NCT07126041Not ApplicableNot Yet Recruiting

Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)

Role: lead

NCT05243654Phase 2Recruiting

Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy

Role: lead

NCT03092817Phase 3Completed

Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)

Role: collaborator

NCT04223674Not ApplicableUnknown

Serological Screen and Treat Trial for Plasmodium Vivax

Role: collaborator

All 6 trials loaded